Abstract
Background:
The TMPRSS2:ERG (T2E) gene fusion is the most common rearrangement in prostate cancer (PCa). It is unknown if these molecular subtypes have a different etiology. We evaluated aspirin and non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) in association with T2E fusion status.
Methods:
Subjects were from a population-based case-control study of PCa. T2E fusion status for prostatectomy cases (n=346) was determined by fluorescence in situ hybridization. Medication use was determined from questionnaires. Logistic regression, controlling for age, race, PCa family history and PSA screening, was used to evaluate the association of T2E fusion status according to medication use.
Results:
T2E fusion was present in 171 (49%) cases, with younger cases more likely to be fusion positive (P<0.01). Current aspirin use was associated with a 37% risk reduction of T2E-positive tumors (adjusted odds ratio (OR) 0.63, 95% confidence interval 0.43–0.93). Aspirin use was not associated with T2E negative PCa (adjusted OR 0.99, 0.69–1.42). There were no associations between PCa fusion status and use of nonaspirin NSAIDs or acetaminophen.
Conclusions:
Aspirin was associated with a significant reduction in the relative risk of T2E fusion positive, but not T2E negative, PCa. As inflammation and androgen pathways are implicated in prostate carcinogenesis, additional studies of anti-inflammatory medications in relation to these PCa subtypes are warranted.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644–648.
Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009; 15: 4706–4711.
Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn M et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 2007; 20: 467–473.
Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66: 8337–8341.
Salinas CA, Kwon EM, Fitzgerald LM, Feng Z, Nelson PS, Ostrander EA et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol 2010; 172: 578–590.
Perron L, Bairati I, Moore L, Meyer F . Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer. 2003; 106: 409–415.
Garcia Rodriguez LA, Gonzalez-Perez A . Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 649–653.
Veitonmäki T, Tammela TL, Auvinen A, Murtola TJ . Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer 2013; 49: 938–945.
Shebl FM, Sakoda LC, Black A, Koshiol J, Andriole GL, Grubb R et al. Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study. Br J Cancer 2012; 107: 207–214.
Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E . Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 2006; 12: 130–135.
Thangapazham RL, Shaheduzzaman S, Kim KH, Passi N, Tadese A, Vahey M et al. Androgen responsive and refractory prostate cancer cells exhibit distinct curcumin regulated transcriptome. Cancer Biol Ther 2008; 7: 1427–1435.
Vane J . The evolution of non-steroidal anti-inflammatory drugs and their mechanisms of action. Drugs 1987; 33: 18–27.
Nguyen DP, Li J, Yadav SS, Tewari A . Recent insights into NF-κB signaling pathways and the link between inflammation and prostate cancer. BJU Int 2014; 114: 168–176v.
Fleshner N, Klotz L . Diet androgens, oxidative stress and prostate cancer susceptibility. Cancer Metastasis Rev 1998-1999; 17: 325–330.
Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL . Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008; 168: 250–260.
Egbers L, Luedeke M, Rinckleb A, Kolb S, Wright JL, Maier C et al. Obesity and prostate cancer risk according to tumor TMPRSS2:ERG gene fusion status. Am J Epidemiol 2015; 181: 706–713.
Summersgill B, Clark J, Shipley J . Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays. Nat Protoc 2008; 3: 220–234.
Prise KM, Davies S, Michael BD . Cell killing and DNA damage in Chinese hamster V79 cells treated with hydrogen peroxide. Int J Radiat Biol 1989; 55: 583–592.
Karanjawala ZE, Murphy N, Hinton DR, Hsieh CL, Lieber MR . Oxygen metabolism causes chromosome breaks and is associated with the neuronal apoptosis observed in DNA double-strand break repair mutants. Cur Biol 2002; 12: 397–402.
Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, Campisi J . Oxygen sensitivity severely limits replicative lifespan of murine fibroblasts. Nature Cell Biology. 2003; 5: 741–747.
Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005; 436: 123–127.
Niethammer P, Grabher C, Look AT, Mitchison T . A tissue-scale gradient of hydrogen peroxide mediates rapid wound detection in zebrafish. Nature 2009; 459: 996–999.
Wu Z, Yuan Y, Geng H, Xia S . Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue. Asian J Androl 2012; 14: 316–319.
Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013; 23: 159–170.
Chen B, Zhao J, Zhang S, Wu W, Qi R . Aspirin inhibits the production of reactive oxygen species by downregulating Nox4 and inducible nitric oxide synthase in human endothelial cells exposed to oxidized low-density lipoprotein. J Cardiovasc Pharmacol 2012; 59: 405–412.
Dragomir E, Manduteanu I, Voinea M, Costache G, Manea A, Simionescu M . Aspirin rectifies calcium homeostasis, decreases reactive oxygen species, and increases NO production in high glucose-exposed human endothelial cells. J Diabetes Complications 2004; 18: 289–299.
Mahmud SM, Franco EL, Turner D, Platt RW, Beck P, Skarsgard D et al. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS One 2011; 6: e16412.
Murad AS, Down L, Davey Smith G, Donovan JL, Athene Lane J, Hamdy FC et al. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study). Int J Cancer 2011; 128: 1442–1448.
Acknowledgements
Research support was given by NIH Grants: R01 CA 092579 (JLS); P50 CA097186 (JLS and DWL); T32 CA009168-30 (JLW); with additional support from the Fred Hutchinson Cancer Research Center, the Prostate Cancer Foundation, and the many men who generously participated in the study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Wright, J., Chéry, L., Holt, S. et al. Aspirin and NSAID use in association with molecular subtypes of prostate cancer defined by TMPRSS2:ERG fusion status. Prostate Cancer Prostatic Dis 19, 53–56 (2016). https://doi.org/10.1038/pcan.2015.49
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2015.49